BeyondSpring presents Phase 2 data showing Plinabulin's potential in metastatic NSCLC after PD-1/L1 therapy, with promising survival rates. BeyondSpring Inc. announced promising interim results from ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

BeyondSpring Inc. has announced its Q1 2025 financial results and provided an update on its clinical programs, highlighting the early efficacy of its drug Plinabulin in treating metastatic non-small ...

Summit Therapeutics' ivonescimab BLA wins FDA acceptance for EGFR-mutated NSCLC, with a PDUFA action date of Nov. 14, 2026.

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced ...

LUND, SE / ACCESS Newswire / October 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and ...

Low-Dose Total Skin Electron Beam Radiotherapy in Stage IB-IIB Mycosis Fungoides: Results From the Prospective S-MISR Study Eftilagimod alpha (efti), an antigen-presenting cell (APC) activator, may ...

TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung ...

New Study Introduces a Personalized Therapy Selection Approach in NSCLC Poised to Transform Treatment Decisions Cellworks Group Inc., a leader in Personalized Therapy Decision Support and ...